US2010291680A1PendingUtilityA1

Methods and compositions for inhibition of membrane fusion-associated events, including hiv transmission

59
Assignee: TRIMERIS INCPriority: Jun 7, 1994Filed: Jun 2, 2010Published: Nov 18, 2010
Est. expiryJun 7, 2014(expired)· nominal 20-yr term from priority
Inventors:Dani P. BolognesiThomas James MatthewsCarl T. WildShawn O'Lin BarneyDennis Michael LambertStephen Robert PettewayAlphonse J. Langlois
A61P 37/04A61P 31/18A61P 31/16A61P 31/22A61P 31/14A61P 31/12Y10S530/826C07K 14/245C12N 2740/17022G01N 33/5091C12N 2710/16222C07K 5/1013C12N 2760/18122A61P 11/00C07K 5/0812C07K 5/0808C07K 14/285C07K 14/21C12N 2740/14022A61K 2039/6031A61K 2039/525C12N 2740/15022A61K 38/00C07K 5/0806C07K 2319/00C07K 14/31C12N 2760/18622C12N 2740/16122C07K 5/1016C07K 5/1021A61K 2039/60G01N 33/5008G01N 33/505C07K 14/22G01N 33/502C12N 7/00C12N 2760/18422C07K 14/005C07K 5/1024A61K 2039/555C12N 2760/18022C12N 2740/16222C12N 2740/13022C12N 2760/18722C07K 5/0817C12N 2760/16122C07K 5/0819C07K 5/101C12N 2760/18522C07K 5/1008C12N 2730/10122A61K 39/00
59
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID NO:1) peptide corresponding to amino acids 638 to 673 of the HIV-1 LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.

Claims

exact text as granted — not AI-modified
1 . An isolated peptide recognized by an ALLMOTI5, 107×178×4 or a PLZIP sequence search motif 
     
     
         2 . The peptide of  claim 1  wherein the peptide corresponds to a peptide present in a virus. 
     
     
         3 . The peptide of  claim 2  in which the virus is HIV-1 or HIV-2. 
     
     
         4 . The peptide of  claim 2  in which the virus is a respiratory syncytial virus. 
     
     
         5 . The peptide of  claim 2  in which the virus is a human parainfluenza virus. 
     
     
         6 . The peptide of  claim 2  in which the virus is an influenza virus. 
     
     
         7 . The peptide of  claim 2  in which the virus is a hepatitis B virus. 
     
     
         8 . The peptide of  claim 2  wherein the virus is an Epstein-Barr virus. 
     
     
         9 . A method for the inhibition of transmission of a virus to a cell, comprising contacting the cell with an effective concentration of a peptide recognized by an ALLMOTI5, 107×178×4 or a PLZIP sequence search motif for an effective period of time so that no infection of the cell by the virus occurs. 
     
     
         10 . The method of  claim 9  wherein the virus is HIV-1 or HIV-2. 
     
     
         11 . The method of  claim 9  wherein the virus is a respiratory syncytial virus. 
     
     
         12 . The method of  claim 9  wherein the virus is a human parainfluenza virus. 
     
     
         13 . The method of  claim 9  wherein the virus is an influenza virus. 
     
     
         14 . The method of  claim 9  in which the virus is a hepatitis B virus. 
     
     
         15 . The method of  claim 9  wherein the virus is an Epstein-Barr virus.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.